Board summary
Key figures
51,930
Registered population
60.8% aged 18–64
17.7%
Aged 65+
ICB 21.9% · England 17.9%
21.4%
Ethnic minority (non-White)
12.1% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
7,177
Hypertension register
-0.36% in 3 yrs · England +5.60%
405
SMI register
31.8% of Crawley's
820
COPD register
Reviews -3.80% in 3 yrs
Forecast to 2030
7,520
Hypertension patients, 2030
+343 on today
77.1%
QRISK ≥20% on statins, 2030
+6.64pp over 3 yrs
4.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Pre-school MMR2 and booster coverage trail.
Age-five MMR2 is 79.9% (15.1 pp below the 95.0% target) and 4-in-1 booster is 78.7%; Woodlands&clerklands Partnership MMR2 is 66.1%.
High-risk lipid therapy lags alongside higher unit cost.
QRISK ≥ 20% lipid therapy is 61.3% (Crawley 65.9%, England 63.6%), while lipid-modifying items cost £2.90 (£69,773 more than at England's £1.86).
Strong hypertension control and improving SMI checks.
Hypertension treatment to target reaches 76.8% (England 70.3%) with 95.8% BP recording, while SMI BMI checks rose +14.5 pp to 84.9%.
Population, age and ethnicity
Patients aged 65+ reach 17.7% alongside a 21.4% ethnic minority resident share
Across 51,930 registered patients, 17.7% (9,212) are aged 65+ (Crawley 13.7%, NHS Sussex Integrated Care Board 21.9%, England 17.9%). Children aged 0-17 comprise 21.5% (Crawley 22.1%, ICB 17.7%, England 19.6%). Census data for associated areas shows a 21.4% ethnic minority resident share, including 12.1% Asian or Asian British residents (Crawley 15.4%, ICB 3.7%, England 9.6%), reaching 16.0% at Ifield Medical Practice and 13.8% at Furnace Green Surgery, alongside 78.6% White residents (Crawley 73.4%, ICB 91.0%, England 81.1%). Projected list growth to 2030 is 3.2% under an unverified methodology.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Crawley local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Crawley LA) | 2,574 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 89.5% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Crawley LA) | 1,205 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Crawley LA) | 12.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
With 0.0% Core20 patients, health inequalities work centres on non-LSOA inclusion cohorts
Healthy Crawley PCN records 0.0% of registered patients in Core20 quintile 1, below Crawley (1.3%), NHS Sussex Integrated Care Board (9.2%) and England (21.0%). The PCN average IMD decile is 6.2 (Crawley 5.1, NHS Sussex Integrated Care Board 6.1, England 5.5). Practice and PCN Core20 shares reconcile at 0.0% across all four practices (0 estimated residents). Practice IMD deciles range from 4.5 at Ifield Medical Practice to 7.3 at Pound Hill Medical Group. Inequalities work should therefore focus on non-LSOA inclusion cohorts rather than area-based outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
405
SMI register
0.76% recorded prevalence
418
Learning disability register
0.79% recorded prevalence
38
Care homes, 734 beds
In the PCN catchment
8.7%
Provide unpaid care
Crawley, Census 2021
The PCN records 418 learning disability patients (0.8%; Crawley 0.8%, ICB 0.6%, England 0.6%) and 405 severe mental illness patients (0.8%; Crawley 0.9%, ICB 1.1%, England 1.0%), comprising 35% and 31.8% of borough registers. Catchment data shows 38 care homes (734 beds), though occupancy is unverified. Substantial borough shares for learning disability and severe mental illness registers indicate significant inclusion health caseloads across primary care.
Severe mental illness: physical health checks
SMI checks reached 84.9% for BMI (England 82.1%) and 84.6% for blood pressure (England 83.4%). However, blood pressure recording stands at 75.3% at Ifield Medical Practice, leaving an uncompleted check gap.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,177
Hypertension register
−0.36%
Register growth, 3 yrs
Crawley +6.33% · England +5.60%
+3.60pp
BP control, under 80
≤140/90 · +0.80pp aged 80+
+343
More patients by 2030
Forecast 7,520 (13.42%)
Hypertension case-finding and control
Hypertension blood pressure recording reached 95.8% (Crawley 93.2%, NHS Sussex Integrated Care Board 90.2%, England 90.0%) and treatment to target was 76.8% (Crawley 74.2%, NHS Sussex Integrated Care Board 69.1%, England 70.3%). Recorded QOF prevalence is 13.5% (7,177 patients; Crawley 13.8%, England 15.2%, NHS Sussex Integrated Care Board 16.3%). However, prevalence three-year change was -0.4%, while expanding in Crawley (+6.3%), NHS Sussex Integrated Care Board (+5.5%) and England (+5.6%). Crude prevalence is not age-adjusted. Strong blood pressure control alongside a contracting register may indicate unrecorded patients, which an opportunistic case-finding audit could test.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy is 61.3% (Crawley 65.9%, England 63.6%, NHS Sussex Integrated Care Board 60.0%). CKD patients treated with lipid lowering therapy reached 68.1% (England 70.3%, Crawley 69.9%, NHS Sussex Integrated Care Board 65.9%). Lower therapy coverage highlights scope to expand lipid prevention in high-risk groups.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 67,089 | £2.90 | £2.42 | £1.86 | £194,558 |
| Cardiovascular (all), 2025 | 91,143 | £3.55 | £3.32 | £3.33 | £323,558 |
In 2026, lipid-modifying drugs cost £2.90 per item across 67,089 items (Crawley £2.34, NHS Sussex Integrated Care Board £2.42, England £1.86), representing £69,773 more than at England's unit cost. This difference is a unit-cost indicator rather than a savings target, reflecting prescribing choices across member practices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.36%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.87%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.3% (3,128 patients; England 6.6%). Annual reviews reached 70.8% (England 65.7%), but varied from 49.6% at Ifield Medical Practice to 85.0% at Woodlands&clerklands Partnership, leaving a scale cohort of about 920 unreviewed patients. Meanwhile, COPD prevalence is 1.5% (820 patients; England 1.9%). While COPD reviews stand at 77.3% (England 76.4%), coverage fell 3.8% over three years (England +2.8%). Asthma prescribing for ages 5-19 is 1,101 per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 4.0% (2,122 patients; England 3.8%). Childhood immunisations show pre-school shortfalls: at age 5, 4-in-1 booster coverage is 78.7% (16.3 pp below the 95.0% target) and MMR dose 2 is 79.9% (15.1 pp below target; England 82.8%). MMR dose 2 ranges from 66.1% at Woodlands&clerklands Partnership to 96.0% at Furnace Green Surgery, with a 12 pp gap between doses at Pound Hill Medical Group.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of staged cancers across NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209 known-stage cases; England 55.3%), below the 75.0% national ambition by 16.5 pp. Known stage was recorded for 64.3% of registered cases (England 67.0%). Reaching 75.0% across the ICB would require about 1,360 additional early-stage diagnoses annually holding staged share fixed. In the PCN, breast screening coverage fell 2.5% over 2023 to 2024 (England +8.4%) to 69.2%. Cervical screening in women aged 25-49 fell 4.0% over 2023 to 2025 (England -1.0%) to 67.0%, with 62.2% at Ifield Medical Practice and 66.3% at Furnace Green Surgery.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Surrey and Sussex Healthcare NHS Trust achieved 70.0% against the 85.0% 62-day cancer referral to treatment standard, below the standard by 15.0 pp (England 71.2%, NHS Surrey and Sussex Integrated Care Board 71.5%), behind Epsom and St Helier University Hospitals NHS Trust (86.8%) and ahead of University Hospitals Sussex NHS Foundation Trust (65.2%). The trust met the 28-day faster diagnosis standard at 77.7% (standard 75.0%, England 79.3%). In Jul 2026 diagnostics, 28.5% of patients at the trust waited 6+ weeks (England 23.1%), including echocardiography (43.8%) and non-obstetric ultrasound (32.3%).
| Pathways within standard (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 74.01 | 89.70 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 76.79 | 99.16 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 65.20 | 86.82 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | England |
|---|---|---|---|---|
| MRI | 27.53 | 5.62 | 0.31 | 21.40 |
| CT | 18.49 | 8.57 | 1.06 | 9.92 |
| Echocardiography | 43.78 | 0.39 | 25.49 | 28.48 |
| Colonoscopy | 15.11 | 39.35 | 33.01 | 30.83 |
| Gastroscopy | 21.06 | 20.02 | 30.90 | 29.02 |
| All 15 DM01 tests | 28.50 | 12.95 | 6.83 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), community health services recorded 78,050 contacts for Crawley borough residents, with 56,740 contacts (72.7%) among adults aged 65 and over. These figures describe borough-level resident activity rather than PCN-registered patients. High older-adult community activity underscores coordinating borough community services with primary care.
Practice variation and patient experience
Vaccination achievement spans 48.4 pp across practices despite uniformly high clinical QOF scores
In 2025/26, QOF vaccination and immunisation achievement spanned 48.4 pp across captured practices, from 17.6% at Pound Hill Medical Group to 66.0% at Furnace Green Surgery (England 55.2%). Clinical-domain achievement was 98.4% at Ifield Medical Practice and 100.0% at Furnace Green Surgery (England 97.1%). This variation may reflect practice-level delivery differences.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Woodlands&clerklands | 95 | 0.0 | 66.5% | 77.1% | 85.1% |
| Ifield Medical | 115 | 0.0 | 74.1% | 71.8% | 84.7% |
| Pound Hill | 108 | 0.0 | 64.0% | 80.4% | 83.6% |
| Furnace Green | 94 | 0.0 | 69.7% | 66.8% | 73.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 compared measures trail England over three years, led by dementia
Over three years, 15 of 25 measures trail England. The widest relative lags are dementia prevalence (-7.5% vs England +6.0%, trailing England by 13.5 points), breast screening (-2.5% vs England +8.4%), and heart failure reviews (+1.2% vs England +8.7%). Stroke prevalence fell 4.4% (England +2.3%). Conversely, strengths include SMI annual BMI recording (+14.5 pp vs England +5.1 pp), psychosis alcohol checks (+14.4 pp vs England +5.4 pp), and statin therapy in diabetes without CVD (+10.2% vs England +2.1%). Diabetes control with frailty reached 89.5% (England 81.9%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Breast screening (53-70)
Heart failure reviews
Stroke register
COPD reviews
BMI record (SMI)
Alcohol record (psychosis)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Crawley | Asset | PCN | Crawley |
|---|---|---|---|---|---|
| Care homes (catchment) | 38 (734 beds) | n/a | Schools (catchment) | 91 | n/a |
| Children's centres | 6 | 7 | Places of worship | 51 | 45 |
| Libraries | 2 | 2 | Food banks (VCS) | 3 | no data |
| Homelessness support (VCS) | 1 | no data | Day centres (VCS) | 6 | 1 |
| Children and young people (VCS) | 1 | no data | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 17 | 10 | Primary academies | 14 | 14 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Pre-school booster and MMR2 recall
In Q1 2025/26, age-5 4-in-1 coverage was 78.7% (below the 95.0% target by 16.3 pp; England 80.9%) and MMR2 was 79.9% (below target by 15.1 pp; 6.9 pp below MMR1 at 86.8%). For discussion: standardise pre-school call-recall templates, audit children with MMR1 who lack MMR2, and test flexible clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
High-risk lipid therapy and formulary review
QRISK ≥ 20% lipid therapy is 61.3% (Crawley 65.9%, England 63.6%) and CKD therapy is 68.1% (England 70.3%); 67,089 lipid-modifying items cost £2.90 each (£69,773 more than at England's £1.86 unit cost). For discussion: run a pharmacist-led search for untreated high-risk QRISK and CKD patients and review lipid-modifying formulary choices. Moderate effort to run.
Option 3
Dementia and stroke register coding audit
Over 2023 to 2025, dementia prevalence fell 7.5% to 0.5% (274 patients; England +6.0%, 0.8%; range -46 to +132) and stroke fell 4.4% to 1.7% (924 patients; England +2.3%, 1.9%). For discussion: audit hospital discharge and care-home records for uncoded dementia or stroke diagnoses across member practices. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored health outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Non-LSOA clinical outreach strategy (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call and recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Digital access and website review (p9) | GPPS easy to contact the practice using its website | 10YHP, hospital to community | Practice |
| Option 1 · Pre-school booster and MMR2 recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · High-risk lipid therapy and formulary review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026 | — | PCN |
| Option 3 · Dementia and stroke register coding audit (p12) | Dementia register · Dementia: QOF prevalence · Stroke register | 66.7% diagnosis ambition · 95% care plan 2027 · Core20PLUS5 CVD · CVDPREVENT · SSNAP | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
